FDA approves GSK's Hibsago for chronic hepatitis B treatment

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. TSLA
6. META
7. RTX
8. SMCI
9. GOOGL
10. S

Go back to FDA approves GSK's Hibsago for chronic hepatitis B treatment

Ionis partner GSK announces Hibsago (bepirovirsen) approved in the U.S. for the treatment of chronic hepatitis B (CHB)

October 20, 2026 9:20 PM EDT

Approval based on Phase 3 data showing unprecedented functional cure rates compared to standard of care
Six-month treatment with option of at-home administration after first dose
CHB affects approximately 1.7 million people in the U.S.

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced... More